For instance, Regeneron Pharmaceuticals, in collaboration with Sanofi, entered Phase 2 clinical trials for asthma, chronic obstructive pulmonary disease and atopic dermatitis with an anti-IL-33 antibody (REGN3500). The gene discussed is IL33; the disease is asthma.